BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, July 17, 2026
Home » Blogs » BioWorld MedTech Perspectives » Med-tech from the battlefield

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

Medical technology

Med-tech from the battlefield

Aug. 12, 2013
By Amanda Pedersen

wounded-warriorsA decade ago it would have been hard to imagine a bioabsorbable tissue-lined stent graft capable of treating blood vessels that have been ripped apart by a bomb, or a spray-on solution that would promote the regrowth of your own skin after a traumatic injury or burn, or even a portable machine that could treat deadly infections like sepsis in much the same way that dialysis machines treat kidney failure. But today these innovations and many more are being developed to treat wounded warriors and will someday be used not just on the battlefield but in civilian hospitals as well. This week Medical Device Daily will be reporting on the various ways that combat needs have influenced R&D for medical technology in a three-part series. Of course this is not a new phenomenon but something that has occurred throughout history, as far back as World War I and beyond. Probably for as long as battles have existed, war wounds have played a role in advancing medicine on the homefront. But what has changed is the types of injuries that combat medics and surgeons have had to deal with during these two most recent conflicts overseas, primarily because the military now has such advanced, high-tech body armor and armored vehicles, that soldiers are now surviving blasts that otherwise might have killed them. That’s why the majority of injuries these wounded warriors suffer from have been quite traumatic and life-altering, like amputations, paralysis and severe burns. As a military spouse I’m sensitive to the sacrifice that these wounded warriors have made and I am grateful that organizations like the Armed Forces Institute of Regenerative Medicine (AFIRM) at Fort Detrick, Maryland have been able to fund so many R&D projects to advance combat treatment. My fear is that as the U.S. pulls out of Iraq and Afghanistan the government will also stop funding this type of research. During an interview with Maj. Louis Alvarez of the AFIRM, he expressed similar concerns. “We want to maintain awareness and visibility of these injuries that will be lifelong and traumatic,” he said. “... We should maintain as much momentum as possible,” on these fronts.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 17, 2026.
  • AI-generated  illustration of a neuron with tau protein aggregation

    AAIC 2026: Age of amyloid is being joined by time of tau

    BioWorld
    The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
  • Senior medical exam

    Celia trial: data strong, analysts skeptical

    BioWorld
    Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 14, 2026
  • Illustration of human brain and dna

    Voyager’s gene therapy reduces tau levels in AD models

    BioWorld Science
    At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical efficacy data for VY-1706, a blood-brain...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
    • Videos
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing